Floatz logo

Mebufotenin

PTSD - Post Traumatic Stress Disorder

Johns Hopkins UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the PTSD - Post Traumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB

View all 44 →

Same molecule, other indications

Mebufotenin is also rated in:

cognitive disorderDormant
B
Indicative ·
61 / 100
View asset →
brain injuryDormant
CCC
Indicative ·
53 / 100
View asset →
Brain InjuriesDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →